Completely revised and updated, this fourth edition elucidates the principles of pharmaceutics, biopharmaceutics, dosage form design, and drug delivery - including emerging new biotechnology-based treatment modalities. The authors integrate aspects of physical pharmacy, chemistry, biology, and biopharmaceutics into drug delivery.
With the expiration of older patents and generic competition, the biopharmaceutical industry is evolving faster than ever. Consequently, this edition of the book emphasizes the heightened focus that the recent remarkable progress in gene editing, immunotherapy, and nanotechnology has brought to the design of new drugs and diagnostic approaches along with novel dosage forms.
Apart from new chapters, this edition highlights the emerging emphasis on the role of artificial intelligence (AI) in drug discovery, mRNA and antibody-based therapies, genome editing, immunotherapy, chemical kinetics, and the stability of drug products.
Features:
· Includes new chapters on antibody therapeutics, gene editing, and immunotherapy.
· Explains newer approaches and future methods and the significance of artificial intelligence (AI) in drug discovery.
· Updated sections on pharmacy mathematics, chemical kinetics, and the stability of medicinal products.
· Important updates on parenteral drug products, protein and peptide treatments, and biotechnology-based pharmaceuticals to provide a contemporary perspective on drug development, delivery, and pharmaceutical sciences.
· Expansion of review questions and answers to clarify concepts for students and add to their grasp of key concepts covered in this book.
Although there are numerous books on pharmaceutics and dosage forms, most cover different areas of the discipline and do not provide an integrated approach. The integrated approach of this book not only provides a singular perspective of the overall field, but also supplies a unified source of information for students, instructors, and professionals, saving their time and money.
¿
Ram I. Mahato is Parke-Davis Endowed Professor and Chairman of the Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE. He was a professor at the University of Tennessee Health Science Center in Memphis, Research Assistant Professor at the University of Utah in Salt Lake City, Senior Scientist at GeneMedicine, Inc., The Woodlands, TX, and as a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He received PhD in Drug Delivery from the University of Strathclyde and BSPS from China Pharmaceutical University. He has published 168 papers, 17 book chapters, holds 4 US patents, and has edited/written 12 books and 14 journal issues (Total Google Citations= 14,609 and h-Index =70). He was a Feature Editor of the Pharmaceutical Research (2006-2013) and Editorial Board Member of eight journals. He is a CRS and AAPS Fellow, Permanent Member of BTSS/NIH Study section, and ASGCT Scientific Advisor. He is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics.
Ajit S. Narang works as a Vice President at Oric Pharmaceuticals in South San Francisco, CA. His primary expertise is in oral drug delivery. He holds over 18 years of pharmaceutical industry experience in the development of oral dosage forms and drug delivery platforms. Previously he worked as a Principal Scientist at Genentech, Inc. and Bristol-Myers Squibb, Co. (BMS) in New Brunswick, NJ in the Drug Product Science & Technology Department. In addition to BMS, he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) and Morton Grove Pharmaceuticals (currently, Wockhardt USA). He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutical Sciences from Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. He currently serves the Excipient Focus Group chair-elect for the American Association of Pharmaceutical Scientists (AAPS), Adjunct Faculty for the UTHSC, and Associate Faculty for the University of Phoenix, AZ. His current research interests include innovations in dosage form development and drug delivery technologies that enable pharmaceutical development of challenging molecules to resolve stability, pharmacokinetic, and pharmacodynamic issues. He has more than 40 publications and three pending patent applications and has contributed to the development of several marketed drug products.
Virender Kumar is an assistant professor of Pharmaceutics in the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo Medical Center. He worked as a Research Assistant Professor and as a postdoctoral at the University of Nebraska Medical Center, Omaha. He received his PhD in Drug Delivery also from the UNMC. He worked as a scientist in A&Z Pharmaceuticals, New York, NY. He received a master in industrial pharmacy from Saint Johns' University, NY. He also received M. Pharm, and B. Pharm from Guru Jambheshwar University, Hisar, Haryana, India. He has published 43 papers, 6 book chapters, holds 1 US patent, and has edited/written 1 book and two journal issues.
